Hematología y Hemoterapia

Resultados: 408
Tipo Título / Nombre Autor(es) Año
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, Bergua JM, et al 2019
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance García-Marco JA, López Jiménez J, Recasens V, Fernández Zarzoso M, González-Barca E, Somolinos De Marcos N, et al 2019
Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing Bastida JM, Morais S, Palma-Barqueros V, Benito R, Bermejo N, Karkucak M, et al 2019
Coexistence of ymphoplasmacytic lymphoma, multiple myeloma and myelodysplastic syndrome Cáceres Hernández S, Bañas Llanos H, Arcos Carmona MJ, Cardesa Cabrera R, Suárez Varela S, Casas Avilés I, et al 2019
LMA NPM1 tras TE JAK2V617F: ¿transformación leucémica u origen de novo? Moriano Palacios BJ, Ferre Bermejo O, Cardesa Cabrera R, Suárez-Varela Pineda S, Cáceres Hernández S, Rodríguez López A, et al 2019
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, et al 2019
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, et al 2019
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G4, Pérez-Oteyza J, García-Boyero R, et al 2019
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, et al 2019
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al 2019